Short Summary
Nexus Pharmaceuticals' PGR challenge against Exela Pharma Sciences was denied institution because the arguments regarding enablement, written description, and obviousness were largely identical to those previously presented during prosecution. The Board found that the Patent Owner successfully demonstrated how process controls overcome prior rejections, leading to a denial of the petition under § 325(d).
Detailed Summary
Nexus Pharmaceuticals LLC challenged claims 1-30 of Exela Pharma Sciences' patent (No. 11642370) on grounds including lack of enablement, written description, and obviousness. The Patent Owner successfully argued that the petition should be denied institution under 35 U.S.C. § 325(d), asserting that similar arguments had already been presented to the Office during prior prosecution and earlier PGR proceedings. The Board agreed, finding that the Petitioner failed to demonstrate a material error because the Patent Owner had previously overcome enablement rejections by demonstrating control over variables like reduced oxygen and aluminum levels using processes taught in the specification. Consequently, the institution of the petition was denied.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Nexus Pharmaceuticals LLC vs Exela Pharma Sciences, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
3D Systems Corporation et al.vsIntrepid Automation, Inc.
The USPTO granted institution for five IPR proceedings (IPR2025-01042, IPR2025-01241, IPR2025-01264, IPR2025-01153, and IPR2025-01242) after determining the petitioner had a reasonable likelihood of prevailing.
Microsoft Corp.vsVirtaMove, Corp.
Microsoft has filed a petition to invalidate 18 claims of VirtaMove’s ’058 patent, alleging obviousness over the Callender patent. The petition argues that Callender is prior art under §102(e) and renders the claims unpatentable under §103.
Paragon 28, Inc.vsTREACE MEDICAL CONCEPTS, INC.
Treace Medical announced a confidential settlement with Fusion Orthopedics, ending a patent infringement lawsuit tied to its Lapiplasty bunion‑correction system. The settlement concludes the related PGR proceeding (PGR2026‑00017).
Disney Entertainment & Sports LLCvsAdeia Media Holdings Inc.
Disney has filed an IPR petition seeking cancellation of all 13 claims of U.S. Patent 8,280,987, alleging obviousness over CDN‑related prior art (Dilley, Russell) combined with Menon. The petition includes detailed claim‑construction arguments for key terms.
Samsung Electronics Co., Ltd. et al.vsStaton Techiya, LLC
Samsung Electronics has filed a Petition challenging Staton Techiya's patent (11710473) on grounds of obviousness under 35 U.S.C. §103. The challenger argues that the claimed audio processing and ambient sound control features are merely combinations of prior art teachings from Kirsch, DiCenso, Goldstein, and Woodruff. This challenge targets a broad range of claims related to earpiece functionality.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.